All In Biotech

NDA 019668 · Viatris

Cardura

Doxazosin Mesylate · Oral

Novel

Last checked: Nov 19, 2026Latest source record: Jun 23, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1990

Nov 2, 1990

Approved uses

1

Original approval plus efficacy supplements

Registered trials

59

6 Phase 3, 0 recruiting

FAERS reports

35,916

29,638 serious, 3,084 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 24, 2025.

Doxazosin is an alpha 1 adrenergic antagonist indicated for: Signs and symptoms of Benign Prostatic Hyperplasia (BPH) ( 1.1 ) Treatment of Hypertension ( 1.2 ) 1.1 Benign Prostatic Hyperplasia (BPH) Doxazosin tablet is indicated for the treatment of the signs and symptoms of BPH. 1.2 Hypertension Doxazosin tablet is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been...

Mechanism: Benign Prostatic Hyperplasia (BPH) The symptoms associated with benign prostatic hyperplasia (BPH), such as urinary frequency, nocturia, weak stream, hesitancy, and incomplete emptying are related to two components, anatomical (static) and functional (dynamic). The static component is related to an increase in prostate size caused, in part, by a proliferation of smooth muscle cells in the prostatic stroma. However, the severity of BPH symptoms and the degree of urethral obstruction do not correlate well with the size of the prostate. The dynamic component of BPH is associated with an increase...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 2, 1990 Original approval · Type 1 - New Molecular Entity
4 products under this application
  • CARDURA · DOXAZOSIN MESYLATE EQ 4MG BASE · TABLET, ORAL · Prescription · TE AB
  • CARDURA · DOXAZOSIN MESYLATE EQ 1MG BASE · TABLET, ORAL · Prescription · TE AB
  • CARDURA · DOXAZOSIN MESYLATE EQ 8MG BASE · TABLET, ORAL · Prescription · TE AB
  • CARDURA · DOXAZOSIN MESYLATE EQ 2MG BASE · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Doxazosin" as an intervention, any sponsor and status, largest first.

All 59 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea1,987
  • fatigue1,755
  • dizziness1,719
  • diarrhoea1,694
  • drug ineffective1,605
  • nausea1,490
  • hypotension1,309
  • acute kidney injury1,268
  • headache1,268
  • asthenia1,247
  • hypertension1,159
  • drug interaction1,118

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004687
2005703
2006718
2007747
2008704
2009853
20101,096
20111,351
20121,374
20131,270
20141,597
20152,001
20162,146
20172,066
20182,559
20192,741
20202,104
20211,894
20221,929
20231,951
20242,070
20251,955
20261,399

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Cardura (Doxazosin Mesylate)

2024 spending

$384K

Beneficiaries

183

711 claims

Per beneficiary

$2,097

$5.87 per unit

View as table
YearSpending
2020$1,159,081
2021$717,905
2022$516,256
2023$465,074
2024$383,733

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 510 on PubMed

Sponsor: Viatris

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.